CME Group Chairman and Chief Executive Officer Terry Duffy to Present at Piper Sandler Global Exchange and Trading Conference
CHICAGO, May 30, 2025 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that Terry Duffy, Chairman and Chief Executive Officer, will present at the Piper Sandler Global Exchange and Trading Conference on Thursday, June 5, 2025, at 1:30 p.m. (Eastern Time).
The presentation will be available for livestreaming via CME Group's Investor Relations website. Please allow extra time prior to the presentation to visit the site and download the streaming media software required to listen to the online broadcast. An audio webcast will be available for replay at the same address approximately 24 hours following the conclusion of the conference.
As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.
CME-G
View original content:https://www.prnewswire.com/news-releases/cme-group-chairman-and-chief-executive-officer-terry-duffy-to-present-at-piper-sandler-global-exchange-and-trading-conference-302469526.html
SOURCE CME Group
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Down 24%, Should You Buy the Dip on BigBear.ai?
The company's share price is down as it struggles to deliver revenue growth. The company isn't profitable despite the best efforts of multiple CEOs. The artificial intelligence analytics market is still promising. 10 stocks we like better than › Many companies that sell artificial intelligence (AI) services have seen their share price skyrocket over the past couple of years. AI data analytics company (NYSE: BBAI) has seen significant volatility, but it has also benefited from bullish market sentiment. The company's share price has surged 142% over the past 12 months, dwarfing the 11% return of the S&P 500. That said, it has also lost a lot of ground lately with a 24% decline in just the past three months. The recent dip no doubt has some investors wondering if this is a great time to buy stock or a warning sign to stay away. The company still has a lot to prove, and here are three reasons investors should leave this AI stock alone right now. Small companies that are tapping into such a fast-growing and in-demand market like AI should experience rapid sales growth. And yet BigBear managed to increase its revenue just 5% year over year to $34.8 million in the most recent quarter. Unfortunately, this appears to be a pattern for the company. Revenue was flat in 2023 and up just 2% in 2024. This year, management says sales could increase 7% (at the midpoint of its guidance). That's unimpressive growth for such a young AI company. For comparison's sake, fellow AI data analytics company Palantir Technologies grew sales 29% last year to $2.9 billion. Typically, high-growth companies experience lots of top-line expansion early on, and investors hope that momentum eventually leads to profits. But with sales growth has been missing for years. reported an adjusted EBITDA loss of $7.0 million in the first quarter, which was worse than its loss of $1.6 million in the year-ago quarter. Management said costs were primarily driven by increased research and development expenses as well as recurring selling, general, and administrative (SG&A) costs. In either case, the company can't afford to have these expenses continue to outpace sales. For investors hoping profits will soon follow the same pattern as its astronomical share price returns over the past couple of years, it's likely to be a very long wait. This may not be the typical reason investors should steer clear of a company, but it certainly raises some red flags. Leadership is crucial to a company's success, so it's worrying to see under its third CEO since it went public in 2021. The current CEO, Kevin McAleenan, has only been at the helm since January. He was the acting Secretary of the U.S. Department of Homeland Security during the first Trump administration. This government connection has some investors hoping that will be able to secure more government contracts. But what they should really be hoping for is McAleenan to stick around long enough to be able to execute a long-term vision for the company. When you add up the company's leadership changes, weak sales growth, and continued losses, it's clear to me the stock is not a buy right now. In a market full of compelling AI stocks, there simply isn't much that's appealing about a speculative bet on Before you buy stock in consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Down 24%, Should You Buy the Dip on was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Gold's Rally Broke Down in May. It's Still Doing Better Than Stocks.
Gold just wrapped up its worst month since December, but don't count the yellow metal out just yet. Gold futures fell 0.5% to $3,288.90 per troy ounce in May to snap a four-month winning streak, with the metal marking its biggest monthly decline in five months, according to Dow Jones Market Data. Gold is still up 25.1% this year, far outpacing the S&P 500's 0.5% 2025 gain.
Yahoo
an hour ago
- Yahoo
The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates
The Cooper Companies (COO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.23%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $0.92 per share when it actually produced earnings of $0.92, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates three times. The Cooper Companies , which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $1 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 0.67%. This compares to year-ago revenues of $942.6 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The Cooper Companies shares have lost about 12.9% since the beginning of the year versus the S&P 500's gain of 0.1%. While The Cooper Companies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for The Cooper Companies: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.05 on $1.07 billion in revenues for the coming quarter and $3.98 on $4.12 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the broader Zacks Medical sector, Plus Therapeutics (PSTV), is yet to report results for the quarter ended March 2025. This developer of cell therapies is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of +77.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Plus Therapeutics' revenues are expected to be $1.85 million, up 10.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report Plus Therapeutics, Inc. (PSTV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
